Cidara Therapeutics Inc (CDTX) Stock
CDTX is no longer traded. Cidara Therapeutics was acquired by Merck (MRK) in January 2026.
Each CDTX share was exchanged for $221.50 in cash. Prices on this page are historical; the last trade was January 5, 2026 at $221.32.
See Merck (MRK) stock →Cidara Therapeutics stock price history
CDTX final trading statistics
- Final close
- $221.32
- Final trading day
- Jan 5, 2026
- Market cap at delisting
- $6.96B
- Shares outstanding
- 31.45M
- Final 52-week range
- $15.22 – $221.42
- Avg. volume (final 3 mo.)
- 1,361,619
- All-time high (split-adj.)
- $345.20 · Dec 2015
- All-time low (split-adj.)
- $8.56 · May 2022
- Return since IPO
- +1283.2%
- Beta
- 1.53
- Book value / share
- $14.40
- Price / book
- 15.37
Cidara Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $1.27M | -$169.8M | -$30.10 |
| FY2023 | $23.28M | -$22.9M | -$0.24 |
| FY2022 | $64.29M | -$29.8M | -$0.48 |
| FY2021 | $49.57M | -$43.9M | -$0.84 |
| FY2020 | $12.07M | -$72.1M | -$1.81 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Cidara Therapeutics stock FAQ
What happened to Cidara Therapeutics stock?
Cidara Therapeutics was acquired by Merck (MRK) in January 2026. Shareholders received $221.50 in cash for each share. CDTX stock stopped trading on the Nasdaq, with a final close of $221.32 on January 5, 2026.
What did Cidara Therapeutics shareholders receive?
Each CDTX share was converted into $221.50 in cash. The deal was valued at about $9.2 billion.
Is CDTX stock still trading?
No. CDTX was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of CDTX stock?
CDTX closed at $221.32 on its final trading day, January 5, 2026, for a market value of about $6.96B.
What were Cidara Therapeutics's revenue and earnings in its last full fiscal year?
Cidara Therapeutics reported revenue of $1.27M and net income of -$169.8M in fiscal 2024, its last full year as a public company.
When did Cidara Therapeutics go public?
Cidara Therapeutics Inc stock began trading on April 15, 2015.